Risk stratification of anastomotic leakage using eGFR and FIB-4 index in patients undergoing esophageal cancer surgery

2021 ◽  
Author(s):  
Keita Takahashi ◽  
Katsunori Nishikawa ◽  
Yuichiro Tanishima ◽  
Yoshitaka Ishikawa ◽  
Takahiro Masuda ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Risk Stratification ◽  
Anastomotic Leakage ◽  
Cancer Surgery ◽  
Esophageal Cancer Surgery

scholarly journals Predictors and outcome of cervical anastomotic leakage after esophageal cancer surgery

2011 ◽  
Vol 7 (4) ◽  
pp. 448 ◽  
Author(s):  
Ali Aminian ◽  
Rasoul Mirsharifi ◽  
Alipasha Meysamie ◽  
Abbas Alibakhshi ◽  
Nekoo Panahi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Anastomotic Leakage ◽  
Cancer Surgery ◽  
Esophageal Cancer Surgery

Neoadjuvant chemoradiotherapy, chemotherapy, and radiotherapy do not significantly increase the incidence of anastomotic leakage after esophageal cancer surgery: a meta-analysis

2021 ◽  
Author(s):  
Zixian Jin ◽  
Jian Zhang ◽  
Dong Chen ◽  
Sikai Wu ◽  
Penglai Xue ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Randomized Controlled Trials ◽  
Anastomotic Leakage ◽  
Meta Analysis ◽  
Neoadjuvant Chemoradiotherapy ◽  
Significant Risk ◽  
Cancer Surgery ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Esophageal Cancer Surgery

Summary This study investigated whether neoadjuvant therapies, such as neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT), and neoadjuvant radiotherapy (NRT), would affect the incidence of anastomotic leakage (AL) after esophageal cancer surgery. Published randomized controlled trials were reviewed, and the incidence of AL after esophageal cancer was statistically analyzed in each study. Meta-analysis was performed using Revman and Stata software. A total of 17 randomized controlled trials with 2874 patients were reviewed showing that, in general, preoperative neoadjuvant therapies were not significant risk factors for AL after esophageal cancer surgery (relative risk [RR] = 0.82, 95% CI = 0.64–1.04). NCRT and NRT did not significantly increase the risk of postoperative AL in patients with esophageal cancer (RR = 0.81, 95% CI = 0.63–1.05; RR = 0.64, 95% CI = 0.14–2.97, respectively). Moreover, NCT has no significant correlation with the occurrence of AL (RR = 1.01, 95% CI = 0.57–1.80). NCRT, NCT, and NRT do not significantly increase the incidence of gastroesophageal AL after esophageal cancer surgery.

Volume and outcomes after esophageal cancer surgery: the experience of the Region of Lombardy—Italy

2013 ◽  
Vol 65 (4) ◽  
pp. 271-275 ◽  
Author(s):  
Uberto Fumagalli ◽  
Maurizio Bersani ◽  
Antonio Russo ◽  
Alessandra Melis ◽  
Stefano de Pascale ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Surgery ◽  
Esophageal Cancer Surgery

Esophageal Cancer Surgery in Heart Transplant Patients

2005 ◽  
Vol 80 (4) ◽  
pp. 1510-1512 ◽  
Author(s):  
Burkhard H.A. von Rahden ◽  
Hubert J. Stein ◽  
Georg Schmidt ◽  
Holger Bartels ◽  
Matthias Overbeck ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Heart Transplant ◽  
Cancer Surgery ◽  
Transplant Patients ◽  
Esophageal Cancer Surgery

Enteral immuno-enhanced diets with arginine are safe and beneficial for patients early after esophageal cancer surgery

2008 ◽  
Vol 21 (7) ◽  
pp. 619-627 ◽  
Author(s):  
Satoshi Aiko ◽  
Yutaka Yoshizumi ◽  
Takamitsu Ishizuka ◽  
Takuya Horio ◽  
Takashi Sakano ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Surgery ◽  
Esophageal Cancer Surgery
Sign in / Sign up

Export Citation Format

Share Document